
    
      Subjects who successfully completed the YKP509C001 study and could benefit from continued
      exposure to carisbamate.

      This is an open-label (OL), multi-center study of carisbamate in subjects with LGS, with
      safety assessments from Baseline (Visit 1) through the early termination (ET)/end of study
      (EOS) visit.
    
  